Wed, 24th Jul 2013 11:14
JOHANNESBURG, July 24 (Reuters) - South Africa's AspenPharmacare Holdings on Wednesday valued its bid for twoof GlaxoSmithKline's thrombosis drugs and a Frenchfactory at around 700 million pounds sterling, 100 millionpounds of which will be for inventory.
The proposed deal was announced last month, although neithercompany gave a value.
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a...
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:
CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U....
FTSE 100 down 0.3%, FTSE 250 off 0.2% *
(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal...
Glaxosmithkline (GSK)